[Antihypertensive first-line and add-on treatment with a fixed controlled release combination of metoprololsuccinate/hydrochlorothiazide. Prospective doctor's office observational study in 14,964 patients].
Hildemann
S K
SK
Klinische Forschung, Pharmacia GmbH, D-91051 Erlangen.
Fischer
H M
HM
Bohlscheid
V
V
Pittrow
D
D
D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D004232:Diuretics; D004338:Drug Combinations; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage*; D006973:Hypertension / Q000188:drug therapy*; D008790:Metoprolol / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D008875:Middle Aged; D010349:Patient Compliance; D012307:Risk Factors; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage*; D013607:Tablets; D013997:Time Factors; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D004232:Diuretics; D004338:Drug Combinations; D049993:Sodium Chloride Symporter Inhibitors; D013607:Tablets; D006852:Hydrochlorothiazide; D008790:Metoprolol